Supplementary Table 5. Annual antiviral prescription* trends in HBsAg-positive pregnant women, 2002–2021

	Subjects (n)	Lamivudine (n)	Adefovir (n)	Entecavir (n)	Clevudine (n)	Telbivudine (n)	TDF (n)	TAF (n)	Total (n)	Percentage (%)
Total	154,478	583	120	607	65	555	4,260	34	6,224	4.0
2002	2,779	3	0	0	0	0	0	0	3	0.1
2003	8,901	21	0	0	0	0	0	0	21	0.2
2004	9,079	35	0	0	0	0	0	0	35	0.4
2005	8,105	42	0	0	0	0	0	0	42	0.5
2006	8,460	61	1	0	0	0	0	0	62	0.7
2007	9,461	89	8	1	2	0	0	0	100	1.1
2008	9,041	92	5	7	6	0	0	0	110	1.2
2009	8,553	61	9	24	16	0	0	0	110	1.3
2010	8,265	71	18	33	11	45	0	0	178	2.2
2011	8,243	39	25	59	12	91	0	0	226	2.7
2012	9,462	32	23	97	4	154	1	0	311	3.3
2013	10,001	11	9	78	8	97	199	0	402	4.0
2014	10,920	8	8	72	2	48	437	0	575	5.3
2015	10,394	6	6	73	3	43	542	0	673	6.5
2016	9,078	4	4	43	0	36	630	0	717	7.9
2017	7,046	3	1	35	0	20	577	0	636	9.0
2018	6,016	3	1	31	0	16	533	3	587	9.8
2019	4,797	2	1	29	0	4	526	10	572	11.9
2020	3,455	0	0	11	1	1	414	7	434	12.6
2021	2,422	0	1	14	0	0	401	14	430	17.8

HBsAg, hepatitis B surface antigen; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.
*Based on the first antiviral drug used during pregnancy.

 https://doi.org/10.3350/cmh.2025.0214